BR112015022977A2 - métodos para predição de risco de metástase em melanoma cutâneo - Google Patents

métodos para predição de risco de metástase em melanoma cutâneo

Info

Publication number
BR112015022977A2
BR112015022977A2 BR112015022977A BR112015022977A BR112015022977A2 BR 112015022977 A2 BR112015022977 A2 BR 112015022977A2 BR 112015022977 A BR112015022977 A BR 112015022977A BR 112015022977 A BR112015022977 A BR 112015022977A BR 112015022977 A2 BR112015022977 A2 BR 112015022977A2
Authority
BR
Brazil
Prior art keywords
gene expression
metastasis
cutaneous melanoma
genes
risk
Prior art date
Application number
BR112015022977A
Other languages
English (en)
Other versions
BR112015022977B1 (pt
Inventor
Maetzold Derek
Oeschlager Kristen
Willis Cook Robert
Original Assignee
Castle Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Castle Biosciences Inc filed Critical Castle Biosciences Inc
Publication of BR112015022977A2 publication Critical patent/BR112015022977A2/pt
Publication of BR112015022977B1 publication Critical patent/BR112015022977B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • User Interface Of Digital Computer (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo patente de invenção: "métodos para predição de risco de metástase em melanoma cutâneo". a presente invenção refere-se a um método para predição do risco de metástase de um tumor de melanoma cutâneo primário, o método envolvendo a medição de níveis de expressão de gene de pelo menos oito genes selecionados de um conjunto de genes específicos em uma amostra tomada a partir do tumor de melanoma cutâneo primário; determinar uma assinatura de perfil de expressão de gene a partir dos níveis de expressão de gene dos pelo menos oito genes; comparar o perfil de expressão de gene ao perfil de expressão de gene de um conjunto de treinamento preditivo; e proporcionar uma indicação como para se o tumor de melanoma cutâneo primário é uma certa classe de metástase ou risco de tratamento quando o perfil de expressão de gene indica que níveis de expressão de pelo menos oito genes são alterados em uma maneira preditiva conforme comparados ao perfil de expressão de gene do conjunto de treinamento preditivo.
BR112015022977-8A 2013-03-14 2014-02-28 Métodos para predição de risco de metástase em melanoma cutâneo BR112015022977B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783755P 2013-03-14 2013-03-14
US61/783,755 2013-03-14
PCT/US2014/019326 WO2014158696A1 (en) 2013-03-14 2014-02-28 Methods for predicting risk of metastasis in cutaneous melanoma

Publications (2)

Publication Number Publication Date
BR112015022977A2 true BR112015022977A2 (pt) 2017-07-18
BR112015022977B1 BR112015022977B1 (pt) 2022-06-21

Family

ID=50391379

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022977-8A BR112015022977B1 (pt) 2013-03-14 2014-02-28 Métodos para predição de risco de metástase em melanoma cutâneo

Country Status (9)

Country Link
US (5) US20140271545A1 (pt)
EP (3) EP4265740A3 (pt)
AU (3) AU2014241995B2 (pt)
BR (1) BR112015022977B1 (pt)
CA (1) CA2904283A1 (pt)
ES (2) ES2947946T3 (pt)
IL (1) IL241086B (pt)
NZ (1) NZ712575A (pt)
WO (1) WO2014158696A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014241995B2 (en) 2013-03-14 2020-01-16 Castle Biosciences, Inc. Methods for predicting risk of metastasis in cutaneous melanoma
US20170329914A1 (en) * 2016-05-11 2017-11-16 International Business Machines Corporation Predicting Personalized Cancer Metastasis Routes, Biological Mediators of Metastasis and Metastasis Blocking Therapies
WO2017210662A1 (en) * 2016-06-03 2017-12-07 Castle Biosciences, Inc. Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
US20180307741A1 (en) * 2017-04-25 2018-10-25 Intel Corporation Filtering training data for simpler rbf models
WO2019084313A1 (en) * 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System USE OF SDHA AS PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR UREAL MELANOMA
CN109485418B (zh) * 2018-12-14 2021-07-20 华南理工大学 一种高效抗肿瘤铌酸钾钠基压电材料及其制备方法与应用
AU2022406744A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504302D0 (en) * 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
US20070082347A1 (en) * 2005-06-08 2007-04-12 Myriad Genetics, Incorporated Gene variants and use thereof
EP2589961A3 (en) * 2006-09-06 2013-08-07 The Regents of the University of California Molecular diagnosis and classification of malignant melanoma
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
NZ555363A (en) 2007-05-24 2009-11-27 Pacific Edge Biotechnology Ltd Prognosis prediction for melanoma cancer
ES2424329T3 (es) * 2008-03-05 2013-10-01 The Regents Of The University Of California Diagnóstico molecular y clasificación de melanoma maligno
WO2009131733A1 (en) * 2008-04-21 2009-10-29 The Trustees Of Columbia University In The City Of New York Gab2 amplification in melanoma
EP2279416A4 (en) * 2008-04-22 2011-08-24 Univ Washington METHOD FOR PREDICTING THE RISK OF METASTASES
BRPI0914734A2 (pt) * 2008-06-26 2015-10-20 Dana Farber Cancer Inst Inc assinaturas e determinantes associados com metástase e métodos de uso dos mesmos
WO2011039734A2 (en) * 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
WO2012040168A2 (en) * 2010-09-20 2012-03-29 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
WO2012125411A1 (en) * 2011-03-11 2012-09-20 Metamark Genetics, Inc. Methods of predicting prognosis in cancer
AU2014241995B2 (en) 2013-03-14 2020-01-16 Castle Biosciences, Inc. Methods for predicting risk of metastasis in cutaneous melanoma

Also Published As

Publication number Publication date
EP4265740A3 (en) 2024-04-24
EP2971085A1 (en) 2016-01-20
AU2014241995A1 (en) 2015-09-24
US10577660B2 (en) 2020-03-03
US20230077559A1 (en) 2023-03-16
IL241086B (en) 2019-07-31
NZ712575A (en) 2019-08-30
EP3425061A2 (en) 2019-01-09
EP2971085B1 (en) 2018-08-08
CA2904283A1 (en) 2014-10-02
IL241086A0 (en) 2015-11-30
WO2014158696A1 (en) 2014-10-02
US20160273052A1 (en) 2016-09-22
AU2020202536B2 (en) 2022-04-07
EP3425061B1 (en) 2023-06-07
AU2014241995B2 (en) 2020-01-16
AU2020202536A1 (en) 2020-05-07
EP3425061C0 (en) 2023-06-07
BR112015022977B1 (pt) 2022-06-21
ES2947946T3 (es) 2023-08-24
WO2014158696A9 (en) 2014-12-18
ES2690584T3 (es) 2018-11-21
EP4265740A2 (en) 2023-10-25
US20140271545A1 (en) 2014-09-18
AU2022204690A1 (en) 2022-07-21
US20200362419A1 (en) 2020-11-19
EP3425061A3 (en) 2019-04-03
US20140272986A1 (en) 2014-09-18
US11434536B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
BR112015011359A8 (pt) método para indicar uma presença ou não presença de câncer de próstata agressivo, dispositivo de ensaio, kit de teste, produto de programa de computador, e aparelho
BR112015031542A2 (pt) métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
AU2013211850A8 (en) Methods for profiling and quantitating cell-free RNA
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
WO2014200912A3 (en) Mathematical processes for determination of peptidase cleavage
NZ701652A (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
ATE531725T1 (de) Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2016203262A3 (en) Gene signatures predictive of metastatic disease
MX2014006182A (es) Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
MX2022013471A (es) Metodo y composiciones de deteccion y cuantificacion de acido nucleico.
BR112017016752A2 (pt) métodos para determinar o risco de recidiva de câncer de endométrio em um indivíduo, para predizer a recidiva em um indivíduo com câncer de endométrio, para orientar o tratamento em um indivíduo com câncer de endométrio, para detectar a instabilidade de microssatélites, e, para determinar subtipos de câncer
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2014, OBSERVADAS AS CONDICOES LEGAIS